Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Assets: 2022-2024

Historic Current Assets for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $232.8 million.

  • Stoke Therapeutics' Current Assets rose 7.42% to $272.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.4 million, marking a year-over-year increase of 7.42%. This contributed to the annual value of $232.8 million for FY2024, which is 8.09% up from last year.
  • As of FY2024, Stoke Therapeutics' Current Assets stood at $232.8 million, which was up 8.09% from $215.3 million recorded in FY2023.
  • Stoke Therapeutics' 5-year Current Assets high stood at $244.1 million for FY2022, and its period low was $215.3 million during FY2023.
  • For the 3-year period, Stoke Therapeutics' Current Assets averaged around $230.7 million, with its median value being $232.8 million (2024).
  • Its Current Assets has fluctuated over the past 5 years, first decreased by 11.77% in 2023, then grew by 8.09% in 2024.
  • Stoke Therapeutics' Current Assets (Yearly) stood at $244.1 million in 2022, then dropped by 11.77% to $215.3 million in 2023, then rose by 8.09% to $232.8 million in 2024.